Molecular Partners Advances Radio-DARPin Pipeline with Strong Financial Runway — Molecular Partners AG

Event summary

Molecular Partners initiated a Phase 1/2a study of DLL3-targeting Radio-DARPin MP0712 for SCLC and other neuroendocrine cancers, with initial data anticipated in 2026.
The company signed a development agreement with Eckert & Ziegler to enable proprietary Radio-DARPin candidates with a range of isotopes, including 225Ac.
Molecular Partners reported a strong financial position with CHF 93.1 million in cash, providing runway until 2028.
The Phase 2 trial of tumor-localized CD40 agonist MP0317 combined with standard-of-care for cholangiocarcinoma is ongoing with patient dosing.

The big picture

Molecular Partners is making significant strides in targeted alpha radiotherapy with the clinical development of its Radio-DARPin candidates. The company's strong financial position and strategic partnerships position it well for future growth in the biotech industry. The advancement of its pipeline, including the Phase 2 trial of MP0317 and the Phase 1/2a trial of MP0533, highlights its commitment to developing innovative therapies for cancer patients.

What we're watching

Clinical Progress: How the initial data from the Phase 1/2a study of MP0712 will impact the development of Radio-DARPin therapies for SCLC and other neuroendocrine cancers.
Financial Strategy: Whether Molecular Partners' current cash position of CHF 93.1 million will be sufficient to support its operating expenses and capital expenditure requirements until 2028.
Pipeline Expansion: The pace at which Molecular Partners will progress its growing Radio-DARPin pipeline, including the nomination of new candidates and the advancement of MP0726 towards first-in-human imaging.